Clopidogrel News and Research

RSS
Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
New study finds efficacy of novel intravenous blood thinner in women

New study finds efficacy of novel intravenous blood thinner in women

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Administering ticagrelor in the ambulance cuts ischaemic events 24 hours following PCI

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

Janssen, Bayer HealthCare announce results from landmark studies evaluating safety profile of XARELTO in NVAF patients

DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

DAPT Study shows dual antiplatelet therapy reduces bleeding-related mortality

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Prasugrel linked to high-bleeding-risk in patients with stable coronary artery disease

Radial approach superior than femoral one for coronary angiography and PCI for ACS patients

Radial approach superior than femoral one for coronary angiography and PCI for ACS patients

ESC Congress to highlight results from global trials in six press conferences

ESC Congress to highlight results from global trials in six press conferences

Mild head injury patients having lower serum S100B levels unlikely to have intracranial hemorrhage

Mild head injury patients having lower serum S100B levels unlikely to have intracranial hemorrhage

Substantial pharmacogenetic information available on cardiovascular drugs

Substantial pharmacogenetic information available on cardiovascular drugs

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Use of balloon-expandable stent compared with medical therapy increases stroke risk

Use of balloon-expandable stent compared with medical therapy increases stroke risk

Researchers find key protein critical to the success of common anti-platelet drug Plavix

Researchers find key protein critical to the success of common anti-platelet drug Plavix

Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Ambulance administration of antiplatelet medication may help heart attack patients

Ambulance administration of antiplatelet medication may help heart attack patients

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Genetic variants linked to race that explains risk of death among patients taking Plavix after heart attack

Genetic variants linked to race that explains risk of death among patients taking Plavix after heart attack

Anticoagulation therapy with low-dose aspirin can be used with new generation mechanical heart valve

Anticoagulation therapy with low-dose aspirin can be used with new generation mechanical heart valve

New angiographic analysis examines impact of stent thrombosis in patients undergoing PCI

New angiographic analysis examines impact of stent thrombosis in patients undergoing PCI

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis

Bristol-Myers Squibb, Pfizer announce FDA approval of Eliquis for DVT prophylaxis